These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 26079072)

  • 1. Ulcerative colitis-associated hospitalization costs: a population-based study.
    Coward S; Heitman SJ; Clement F; Hubbard J; Proulx MC; Zimmer S; Panaccione R; Seow C; Leung Y; Datta I; Ghosh S; Myers RP; Swain M; Kaplan GG
    Can J Gastroenterol Hepatol; 2015 Oct; 29(7):357-62. PubMed ID: 26079072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colectomy is a risk factor for venous thromboembolism in ulcerative colitis.
    Kaplan GG; Lim A; Seow CH; Moran GW; Ghosh S; Leung Y; Debruyn J; Nguyen GC; Hubbard J; Panaccione R
    World J Gastroenterol; 2015 Jan; 21(4):1251-60. PubMed ID: 25632199
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreasing colectomy rates for ulcerative colitis: a population-based time trend study.
    Kaplan GG; Seow CH; Ghosh S; Molodecky N; Rezaie A; Moran GW; Proulx MC; Hubbard J; MacLean A; Buie D; Panaccione R
    Am J Gastroenterol; 2012 Dec; 107(12):1879-87. PubMed ID: 23165448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Predictors of the Risk of Early Colectomy in Ulcerative Colitis: A Population-based Study.
    Al-Darmaki A; Hubbard J; Seow CH; Leung Y; Novak K; Shaheen AA; Panaccione R; Kaplan GG
    Inflamm Bowel Dis; 2017 Aug; 23(8):1272-1277. PubMed ID: 28719540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Length of hospital stay and associated hospital costs with infliximab versus cyclosporine in severe ulcerative colitis.
    Löwenberg M; Duijvis NW; Ponsioen C; van den Brink GR; Fockens P; D'Haens GR
    Eur J Gastroenterol Hepatol; 2014 Nov; 26(11):1240-6. PubMed ID: 25171024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.
    Taxonera C; Barreiro-de Acosta M; Calvo M; Saro C; Bastida G; Martín-Arranz MD; Gisbert JP; García-Sánchez V; Marín-Jiménez I; Bermejo F; Chaparro M; Ponferrada Á; Martínez-Montiel MP; Pajares R; de Gracia C; Olivares D; Alba C; Mendoza JL; Fernández-Blanco I
    Dig Dis Sci; 2015 Oct; 60(10):3075-84. PubMed ID: 26044830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab for hospitalized patients with severe ulcerative colitis.
    Regueiro M; Curtis J; Plevy S
    J Clin Gastroenterol; 2006 Jul; 40(6):476-81. PubMed ID: 16825928
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis.
    Punekar YS; Hawkins N
    Eur J Health Econ; 2010 Feb; 11(1):67-76. PubMed ID: 19844750
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
    Papamichael K; Rivals-Lerebours O; Billiet T; Vande Casteele N; Gils A; Ferrante M; Van Assche G; Rutgeerts PJ; Mantzaris GJ; Peyrin-Biroulet L; Vermeire S
    J Crohns Colitis; 2016 Sep; 10(9):1015-23. PubMed ID: 27022161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inpatient infliximab is ineffective at preventing colectomy for steroid refractory extensive colitis.
    Andrew RE; Lauria A; Puleo FJ; Berg A; Stewart DB
    J Surg Res; 2017 Nov; 219():18-24. PubMed ID: 29078879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
    Fernández-Salazar L; Muñoz F; Barrio J; Muñoz C; Pajares R; Rivero M; Prieto V; Legido J; Bouhmidi A; Herranz M; Fernández N; Sánchez-Ocaña R; Joao D; Santos F
    Scand J Gastroenterol; 2016; 51(2):186-95. PubMed ID: 26200929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Introduction of anti-TNF therapy has not yielded expected declines in hospitalisation and intestinal resection rates in inflammatory bowel diseases: a population-based interrupted time series study.
    Murthy SK; Begum J; Benchimol EI; Bernstein CN; Kaplan GG; McCurdy JD; Singh H; Targownik L; Taljaard M
    Gut; 2020 Feb; 69(2):274-282. PubMed ID: 31196874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoalbuminemia and Bandemia Predict Failure of Infliximab Rescue Therapy in Acute Severe Ulcerative Colitis.
    Syal G; Robbins L; Kashani A; Bonthala N; Feldman E; Fleshner P; Vasiliauskas E; McGovern D; Ha C; Targan S; Melmed GY
    Dig Dis Sci; 2021 Jan; 66(1):199-205. PubMed ID: 32170473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A review of infliximab use in ulcerative colitis.
    Wilhelm SM; McKenney KA; Rivait KN; Kale-Pradhan PB
    Clin Ther; 2008 Feb; 30(2):223-30. PubMed ID: 18343261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Costs and Quality of Life in Ulcerative Colitis Patients with an Ileal Pouch-Anal Anastomosis, Ileostomy and Anti-TNFα Therapy.
    van der Valk ME; Mangen MJ; Severs M; van der Have M; Dijkstra G; van Bodegraven AA; Fidder HH; de Jong DJ; Pierik M; van der Woude CJ; Romberg-Camps MJ; Clemens CH; Jansen JM; van de Meeberg PC; Mahmmod N; van der Meulen-de Jong AE; Ponsioen CY; Bolwerk C; Vermeijden JR; Siersema PD; Leenders M; Oldenburg B; ;
    J Crohns Colitis; 2015 Nov; 9(11):1016-23. PubMed ID: 26254056
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Living with Ulcerative Colitis Study (LUCY) in England: a retrospective study evaluating healthcare resource utilisation and direct healthcare costs of postoperative care in ulcerative colitis.
    Brookes MJ; Waller J; Cappelleri JC; Modesto I; DiBonaventura MD; Bohm N; Mokgokong R; Massey O; Wood R; Bargo D
    BMJ Open Gastroenterol; 2020 Sep; 7(1):. PubMed ID: 32938582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inpatient Infliximab Biosimilar Cost-Savings: Cost Analysis of Inpatient Treatment with Originator Infliximab (Remicade™) versus Biosimilar Infliximab (Renflexis™) for Acute Severe Ulcerative Colitis.
    Cappuccio JM; Mehta N; Pellish R
    Dig Dis; 2024; 42(5):496-502. PubMed ID: 38797170
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ulcerative Colitis Treatment Patterns and Cost of Care.
    Null KD; Xu Y; Pasquale MK; Su C; Marren A; Harnett J; Mardekian J; Manuchehri A; Healey P
    Value Health; 2017 Jun; 20(6):752-761. PubMed ID: 28577692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome of infliximab treatment in chronic active ulcerative colitis: a Swedish multicentre study of 250 patients.
    Angelison L; Almer S; Eriksson A; Karling P; Fagerberg U; Halfvarson J; Thörn M; Björk J; Hindorf U; Löfberg R; Bajor A; Hjortswang H; Hammarlund P; Grip O; Torp J; Marsal J; Hertervig E;
    Aliment Pharmacol Ther; 2017 Feb; 45(4):519-532. PubMed ID: 28025840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Changing Treatment Strategies on Outcomes in Pediatric Ulcerative Colitis.
    Bolia R; Rajanayagam J; Hardikar W; Alex G
    Inflamm Bowel Dis; 2019 Oct; 25(11):1838-1844. PubMed ID: 31002341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.